TITLE

Eyetech aims to be retina specialists' biotech resource

AUTHOR(S)
Dlugoss, Mark L.
PUB. DATE
June 2005
SOURCE
Ophthalmology Times;6/1/2005, Vol. 30 Issue 11, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the projects being explored by New York-based Eyetech Pharmaceuticals to deliver medical solutions for the betterment of patients who suffer from blinding eye diseases. Implication of the U.S. Food and Drug Administration's approval of Eyetech's pegaptanib sodium injection product for the treatment of neovascular age-related macular degeneration on the biotechnology company's operations; Technologies for eye diseases treatment offered by the company. INSET: Take-Home Message.
ACCESSION #
17330221

 

Related Articles

  • Pipeline.  // Medical Marketing & Media;Feb2005, Vol. 40 Issue 2, p12 

    The article presents news from the pharmaceutical industry. Pfizer Inc. received a setback when the FDA classified its newly approved nerve pain drug Lyrica as a controlled substance, resulting in additional requirements for doctors and pharmacists. Pfizer had been counting on Lyrica to offset...

  • Injection approved for macular degeneration.  // Drug Topics;1/10/2005, Vol. 149 Issue 1, p8 

    Reports on the approval of Pegaptanib sodium injection 0.3 mg from Eyetech Pharmaceuticals/Pfizer, for the treatment of neovascular age-related macular degeneration.

  • FDA Approves Eyetech/Pfizers Macugen.  // Review of Ophthalmology;Jan2005, Vol. 12 Issue 1, p4 

    The article reports that the U.S. food and Drug Administration has approved Macugen injection for the treatment of neovascular age-related macular degeneration. The injection has been developed by Eyetech Pharmaceuticals Inc. and Pfizer Inc. Macugen is the first in a new class of ophthalmic...

  • An Update on Macugen Trials. Kulkarni, Kaushal; Prenner, Jonathan L. // Review of Ophthalmology;Dec2005, Vol. 12 Issue 12, Special section p6 

    The article presents information on the VEGF Inhibition Study in Ocular Neovascularization (VISION) study in its second year and on a trial of Macugen for diabetic macular edema. Macugen is used in curing exudative Age-related Macular Degeneration. It is also known as pegaptanib sodium and is...

  • Priority review for Pfizer, Eyetech AMD drug.  // PharmaWatch: Biotechnology;October 2004, Vol. 3 Issue 10, p11 

    The article reports that Macugen, a treatment for age-related macular degeneration jointly developed by Pfizer Corp. and Eyetech Pharmaceuticals Inc. has been granted a priority review designation by the U.S.Food and Drug Administration (FDA). The companies submitted the final portion of the new...

  • New Eye Drug Approved. Mirasol, Feliza // Chemical Market Reporter;1/10/2005, Vol. 267 Issue 2, p10 

    Reports on the approval of the U.S. Food and Drug Administration to new eye drug Macugen of Eyetech Pharmaceuticals Inc. and co-developer Pfizer Inc. Use of Macugen in the treatment of neovascular age-related macular degeneration; Price of the drug; Development of Macugen.

  • Research.  // Journal of Visual Impairment & Blindness;Jan2005, Vol. 99 Issue 1, p55 

    Reports on the approval received by Eyetech Pharmaceutical and Pfizer for the eye treatment Macugen. Benefits of Macugen for patients; Eye disease that can be treated by the drug.

  • Eyetech and Archemix Collaborate on Drugs for Eye Disease. Mirasol, Feliza // Chemical Market Reporter;4/26/2004, Vol. 265 Issue 17, p10 

    Reports on the initiative of Eyetech Pharmaceuticals Inc. to collaborate with Archemix Corp. for the development of drugs on eye disease in the U.S. Terms of the deal; Inclusion of the research and development contracts for the discovery of aptamers for ophthalmic indications; Presentation of...

  • EYETECH GETS EXCLUSIVE LICENSE FOR GILEAD'S AMD TREATMENT.  // Worldwide Biotech;May2000, Vol. 12 Issue 5, p2 

    Announces the worldwide license received by Gilead Sciences Inc. and EyeTech Pharmaceuticals Inc. for its investigational therapy for age-related macular degeneration.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics